Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 20,936 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-treatment Clear all

Conditions: Vitiligo
Interventions: ruxolitinib, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 44
States / cities: Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 26
States / cities: Los Angeles, California • Sebastopol, California • Stamford, Connecticut + 23 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years to 90 Years · Female only
Enrollment: 2,303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Non Small Cell Lung Cancer
Interventions: AC0010MA; Drug
Lead sponsor: ACEA Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Duarte, California • Palo Alto, California • Atlanta, Georgia + 1 more

Conditions: Lung Non-Small Cell Carcinoma, Pleural Disorder
Interventions: Porfimer Sodium, Video-Assisted Thoracic Surgery, Photodynamic Therapy, Intraoperative PDT; Drug · Procedure · Device
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Carboplatin, Etoposide, Lamivudine; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Transplanted Organ Rejection
Interventions: FCR001; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more

Conditions: Graft -Versus-host-disease
Interventions: Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab; Procedure · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Substance-related Disorders
Interventions: referral to work focused program, treatment as usual; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions: No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy; Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: HealthPROMISE users, Control Group; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Adults
Interventions: Follistatin and klotho gene therapy; Genetic
Lead sponsor: Minicircle; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 42
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more

Conditions: Ovarian Cancer, Epithelial, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Streamlined Education, Traditional Education; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hospitalization
Interventions: Care Transitions Innovation (C-TraIn); Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-hRKp.RPGR; Biological
Lead sponsor: MeiraGTx Ocular UK Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions: Testosterone Enanthate, Locomotor Training; Drug · Behavioral
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Perioperative Nutrition
Interventions: Clear Liquids, Standard of Care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain
Interventions: Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bradenton, Florida + 4 more

Conditions: Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions: IGC-AD1-Active, IGC-AD1-Placebo; Drug
Lead sponsor: IGC Pharma, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more

Conditions: Sleep Disorders, Circadian Rhythm, Pain, Rehabilitation, Mood Lability
Interventions: Re-section of a large left anterior cranial fossa meningioma; Procedure
Lead sponsor: Child Psychopharmacology Institute; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Post-cesarean Pain
Interventions: TrueRelief device, Sham TrueRelief device; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, thiotepa, allogeneic bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Women's Health Initiative Study of Cognitive Aging

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

Impact of Work Activity on SUD Outcomes

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life

Safety and Efficacy of Klotho and Follistatin Gene Therapy

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

Care Transitions Innovation (C-TraIn)

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

Clears On the Day of Anesthesia Permissible up to One-Hour Prior (CODA-POP) to Surgery

A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies

Clinical Trial on Agitation in Alzheimer's Dementia

Actigraphic Measurement of a Neurosurgical Procedure

TrueRelief Efficacy for Post-cesarean Pain (ELECTRON)

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer